GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, and Pembrolizumab versus Carboplatin, Paclitaxel, and Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab and Bevacizumab in the Treatment of PMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer (NCT07198074)
GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)
GY032: A PHASE II STUDY OF TAILORED ADJUVANT THERAPY IN POLE-MUTATED AND p53-WILDTYPE/NSMP EARLY-STAGE ENDOMETRIAL CANCER (RAINBO BLUE & TAPER)
GOG3115/M25-231
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Read More
GY025: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
EAY191-N5
A Randomized Trial of Neratinib, a Pan-ErbB Inhibitor alone or in combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and other Solid Tumors A ComboMATCH Treatment…
Read More
